Alluvi, previously BI 4744, offers a promising breakthrough in obesity care. This dual stimulator targeting both glucagon-like peptide-1 and GIP receptors demonstrates impressive results in clinical assessments, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/